Indivior PLC (LON:INDV) insider Lorna Parker bought 11,529 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were acquired at an average cost of GBX 43 ($0.56) per share, with a total value of £4,957.47 ($6,477.81).
Shares of Indivior stock opened at GBX 52.76 ($0.69) on Thursday. Indivior PLC has a 1 year low of GBX 20.98 ($0.27) and a 1 year high of GBX 504.60 ($6.59). The firm has a market cap of $385.16 million and a PE ratio of 1.55. The company has a quick ratio of 1.70, a current ratio of 1.79 and a debt-to-equity ratio of 223.31.
Several equities research analysts have recently issued reports on INDV shares. Numis Securities reaffirmed a “buy” rating on shares of Indivior in a research report on Wednesday, April 10th. Citigroup reaffirmed a “neutral” rating and set a GBX 150 ($1.96) target price on shares of Indivior in a research report on Thursday, May 2nd. Jefferies Financial Group lowered Indivior to a “hold” rating and decreased their target price for the company from GBX 118 ($1.54) to GBX 114 ($1.49) in a research report on Monday, February 18th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a GBX 130 ($1.70) target price on shares of Indivior in a research report on Wednesday, April 10th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of GBX 194.40 ($2.54).
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Further Reading: Derivative
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.